As the biologics landscape grows increasingly complex, CDMOs are under pressure to deliver more than additional manufacturing capacity. Emerging biotechs...
As the biopharmaceutical industry enters a new phase of growth, manufacturers are under increasing pressure to deliver greater capacity, accelerate...
During BIO 2026, taking place June 22–25 at the San Diego Convention Center, BioPharma Boardroom spoke with Francis...
As biopharmaceutical innovation continues to evolve, analytical science is playing a more strategic role in accelerating development and supporting regulat...
The biologics development landscape is becoming increasingly complex, requiring partners that offer more than manufacturing capacity alone. As biotech comp...
BIO 2026, taking place June 22–25 at the San Diego Convention Center, arrives at a time when genomic medicine is rapidly reshaping the future of heal...
Contamination control is no longer viewed solely through the lens of compliance. Across today's biopharmaceutical manufacturing landscape, it has become a ...
BIO 2026, taking place June 22–25 at the San Diego Convention Center, comes at a pivotal moment for emerging biotech companies. While scienti...
As biotech innovators pursue increasingly complex therapies, the path from discovery to clinical proof of concept is becoming more challenging than ever. F...
NDA submission supported by positive Phase 3 data recently published in JAMA Neurology. Ecopipam is a first-in-class selective dopamine D1 receptor an...
The Novo Nordisk Foundation is funding a new pan-European initiative to accelerate drug discovery and the development of next generation therapeutics for...
The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any pr...
Non-dilutive funding will support the commercialization, development, and expansion strategy for Sonire's Ultrasound-Guided HIFU Platform Sonire Therape...
The study achieved the primary endpoint of non-inferiority, with a rate of all-cause mortality (ACM) at Day 42 for olorofim of 23.8% and for AmBisome&r...
© 2026 Biopharma Boardroom. All Rights Reserved.
